

7 August 2014

Company Announcements Office Australian Securities Exchange

Nanosonics announces trophon[®] EPR approval in Japan

Nanosonics (ASX:NAN), a leader in infection control solutions, today announced the regulatory approval of trophon[®] EPR in Japan.

"Japan is an important market as part of our overall strategic growth agenda," said Michael Kavanagh, Nanosonics Chief Executive Officer and President. "It is a significant market globally from an ultrasound perspective and represents an important opportunity for our trophon EPR technology."

"The approval comes earlier than expected which is a credit to our regulatory team's efforts. We are currently finalising the Japanese product variant for introduction into manufacturing as well as our overall commercialisation strategy and expect to enter the Japanese market in the second half of the 2015 financial year," said Mr. Kavanagh.

Further details will be provided at time of market launch into Japan.

Michael Kavanagh CEO / President

For more information please contact: Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600 Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722 / kwilliamson@buchanwe.com.au Ben Oliver, Media Relations, Buchan Consulting on (03) 9866 4722 / bolkanwe.com.au

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries. For more information about Nanosonics please visit <u>www.nanosonics.com.au</u>